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Abstract 
 
Background: The evidence review process for adding new conditions to State Newborn 
Screening (NBS) panels relies on data from pilot studies aimed at assessing the potential 
benefits and harms of screening. However, the consideration of ethical, legal and social 
implications (ELSI) of screening within this research has been limited. This paper outlines 
important ELSI issues related to newborn screening policy and practices as a resource to 
help researchers integrate ELSI into NBS pilot studies.   
 
Methods: Members of the Bioethics and Legal Workgroup for the Newborn Screening 
Translational Research Network facilitated a series of professional and public discussions 
aimed at engaging NBS stakeholders to identify important existing and emerging ELSI 
challenges accompanying NBS.  
 
Results: Through these iterative engagement activities we identified a set of “key ELSI 
questions” related to 1) the types of results parents may receive through of newborn 
screening and 2) the implementation and initiation of NBS for a condition within the NBS 
System. 
 
Conclusion: Integrating ELSI questions into pilot studies will help NBS programs to better 
understand the potential impact that screening for a new condition may have for newborns 
and families and to make crucial policy decisions aimed at mitigating the potential negative 
health and/or social implications of screening.   
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Introduction 
Newborn screening (NBS), a population-based screening program, is required for 
every newborn in the United States1 2.  For over fifty years, NBS has led to the identification 
and early treatment of tens of thousands of newborns for selected birth defects3 4.  US state-
based NBS programs began with screening for phenylketonuria in the 1960’s and expanded 
to include a variety of other conditions as screening technologies developed, clinical 
understanding improved, and treatments became available.  Each state ultimately decides 
which conditions to include, or exclude, in their statewide NBS program.  In addition, the 
Secretary of Health and Human Services, considering the advice of the Advisory Committee 
for Heritable Disorders of Newborns and Children (ACHDNC), recommends conditions for 
screening, termed the Recommended Uniform Screening Panel (RUSP).  ACHDNC and state 
decisions to recommend the addition of new conditions include processes that examine the 
evidence of the potential net benefit of screening, the ability of states to screen for the 
disorder, and the availability of effective treatments5.  Historically, the consideration of 
ethical, legal and social implications (ELSI) within these evidence review processes has 
been limited, generally because researchers have not included a systematic study of ELSI 
issues within NBS research studies.  The goal of this paper is to systematically outline 
important ELSI issues related to NBS policy and practices as a resource to help researchers 
integrate ELSI into NBS pilot studies, or “systematic investigations or public health activities 
that are designed to evaluate the efficacy and safety of incorporating a new test or 
condition on a population-based level into state NBS programs”6.  
As researchers, clinicians, NBS policy makers, and federal agencies have reviewed 
evidence related to the harms and benefits of mandating screening of newborns for a new 
condition, some of their deliberations have included ELSI issues including discussions of 
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permission, the availability of treatments and their costs, and the disparity caused by state-
based variability in the number and types of conditions screened.  Within the context of 
NBS, previous NBS ELSI research studies have examined issues such as the impact of false 
positives or uncertain results on families and the ethical implications of storing and using 
residual blood spots for future research.7  8 9 10 11  However, the extent of this research has 
been limited and except in a few cases12 13 most ELSI studies associated with NBS have not 
been conducted as part of pilots investigating the benefits and harms of adding a new 
condition.  Policy decisions at the federal and state levels to recommend and/or add new 
conditions to routine NBS rely on the data generated during pilots, and the lack of an ELSI 
focus in pilots has led to a paucity of empirical data related to ELSI within the NBS setting.  
Pilots that explore ELSI components could contribute important data for the evidence 
review process designed to evaluate new conditions for NBS.  Any systematic evaluation of 
benefits or harms regarding expanding NBS panels is hindered by this ELSI research gap.  
Additionally, continued advances in our understanding of disease and the introduction of 
new screening technologies raise new ELSI concerns, such as when to report carrier status, 
when to offer testing to additional family members, or the possible psychosocial impact of 
false positives, that warrant further research to improve understanding of these issues and 
provide a basis for policy decisions.14 15 16 17 18 
This paper systematically outlines the crucial ELSI issues related to NBS and to help 
researchers integrate a robust consideration of these issues into NBS pilot studies.  To do so, 
we have identified nine “key ELSI questions” that represent important ethical or social 
challenges for NBS policy and practice.  Our goal is to promote the incorporation of these 
questions when implementing NBS pilot studies to add to the evidence base for making 
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informed policy and practice decisions.  We posit that ELSI data that are collected as part of 
pilot studies can allow the ACHDNC and state NBS programs to better address ELSI 
systematically within their evidence review processes, and mitigate potential negative 
impacts on newborns, their families, and the public health system through empirically 
informed policy and practice changes.  We recognize that there are also a number of 
research ethics challenges related to the design and implementation of NBS pilot studies 
themselves, including human research subjects protections issues related to recruitment 
and study design,  However, these important research process questions are beyond the 
scope of this paper.  For example, while ELSI questions related to the potential need for 
parental permission for new screened conditions are raised here, the permission 
requirements for enrolling participants in a pilot study are not.  Future work in this area 
will be needed to address these important, yet distinct, research ethics questions.  
 
Deliberative Approach  
The key questions presented in this paper were developed through a series of 
professional and public discussions aimed at engaging multiple NBS stakeholders to help 
identify important existing and emerging ELSI challenges accompanying NBS.  These 
questions began with activities of a Parent Project Muscular Dystrophy (PPMD)19 workgroup 
focused on ELSI issues raised by piloting NBS for Duchenne Muscular Dystrophy (DMD).  
Members of the National Institute of Health’s (NIH) Eunice Kennedy Shriver’s National 
Institutes of Child Health and Human Development’s (NICHD) Newborn Screening 
Translational Research Network’s (NBSTRN)20 Steering Committee and the Bioethics and 
Legal Workgroup then discussed these questions, developing a series of general ethical 
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issues that should be addressed by any NBS pilot study.  This workgroup is made up of 
more than twenty NBS stakeholders whose goal is to provide expert advice on issues 
pertaining to newborn screening research, and includes NBS Program Officials, Bioethicists 
and Social Scientists, Geneticists, Laboratory Officials, Layers, and biomedical researchers.  
An early draft of these key questions was presented and discussed at the NBSTRN’s annual 
network meeting in Fall 2016.  This meeting included an additional 100 NBS stakeholders 
including NBS program officials, laboratory directors, NBS researchers, and representatives 
of disease advocacy organizations.  Finally, these questions were posted and discussed on a 
public forum, the NBS Public Square hosted by Genetic Alliance through Babies First Test21, 
the National Newborn Screening Clearinghouse, and funded by Health Resources and 
Services Administration (HRSA).   Each of the engagement exercises was meant to solicit 
informed opinions from NBS stakeholders to iteratively refine and enhance the content of 
this paper.  For example, stakeholders from the NBSTRN Network Meeting aided 
significantly in defining the potential harms of false positives and false negatives, while 
responses from our online discussion forum led to the addition of questions related to 
equity health disparities.   
 
Essential ELSI Research Questions 
The following sections review nine key ELSI questions divided the into two main 
categories:  1) ELSI issues associated with the results of screening, and 2) ELSI issues 
anticipated in the implementation and initiation of NBS for a condition within the NBS 
System.  Specific examples of possible research questions are provided in Table 1.  Each of 
these sets of questions may impact one or more NBS stakeholder groups including: 1) 
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newborns, 2) families, 3) state NBS programs, 4) clinicians and the larger health care 
delivery system, and 5) the general population.  We also recognize that ELSI issues vary 
depending on the specific condition, and some may raise unique challenges for families and 
other NBS stakeholders.  Additionally, not all pilot studies will need, or be able, to answer 
every question from each of these sets of ELSI issues.  
 
ELSI Questions Raised by NBS Results related to a Screening for a Condition 
 
The result-related ELSI questions focus on outcomes related to the analytical and 
clinical validity or utility of the screening test or of the subsequent diagnostic tests.  From 
any screen there are a number of possible results including positive, negative, false positive 
or false negative.  NBS programs continually work to minimize the potential ambiguity or 
negative implications of screening results.  For example, programs strive to reduce the 
number of false positive and false negative results to mitigate any potential physical or 
psychosocial harm to newborns and families.  Nevertheless, as NBS programs add 
conditions and utilize new technologies, there will be need for ongoing ELSI research to 
continually understand the potential impacts, including benefits and harms, that NBS 
results may have for families, and utilize that data to make crucial policy decisions aimed at 
mitigating the potential negative physical or social implications of screening.  Results of 
ELSI studies may, for example, lead to improved screening algorithms, raise difficult 
decisions about what kinds of results physicians or the NBS program should return to 
parents, how those results may impact the screened infants and their families, and whether 
or how to insure that the information from the screening and diagnosis processes becomes 
a part of the child’s health care record.  




Key Question 1: What are the potential ELSI implications of positive screening 
results related to a condition?  
Screening tests do not provide a diagnosis, but rather detect indicators of increased 
risk.  A diagnostic test establishes the presence (or absence) of a disorder.  When the 
screening test result is positive and the diagnosis is confirmed, the family may receive a 
diagnosis before the infant’s disease is clinically observable—this is one of the primary 
goals of NBS.  
ELSI: The ethical or social issues associated with a positive result relate primarily to 
assessing the benefits of screening as well as the potential physical harms and financial 
burdens associated with the diagnostic process following the screen.  These concerns are 
especially salient for conditions where diagnostic testing and treatments are more invasive 
or where long term medical impact or benefits of interventions are less clear.  Additionally, 
as programs have expanded, there are increasing numbers of conditions with later and 
adult onset variants, further complicating diagnostic and treatment decisions.22  While 
these issues are a core concern for NBS programs generally, they raise a number of 
important ethical concerns related to the harms and benefits of screening.  Additionally, an 
out of range result may bring worry, confusion, anger, depression, and even despair to a 
family. 23,24, 25  However, to date there are few published studies that look at the potential 
adverse psychosocial or emotional impacts of non-NBS health screening results for most 
individuals and  families.  Pilot studies that include an ELSI focus are needed to evaluate 
screening protocols for new conditions and compare the net benefits of screening with the 
potential harms of screening and diagnostic procedures and help to address this gap in the 
  10 
context of NBS..  These studies could also address the impact of different approaches to 
education and communication aimed at helping families understand screening information, 
and identify those at most-risk for distress who may need further psychological support.  
 
Key Question 2: What are the potential ELSI implications of false positive screening 
results related to a new condition? 
Screening tests, unlike diagnostic tests, generate relatively large numbers of 
patients needing further evaluation to clarify screening results.  The need for such re-
assessment may have implications for many stakeholders, particularly since the recall rate 
can vary significantly from state to state, depending on the screening protocol and the 
adherence to quality assurance by the state NBS laboratory.  While the goal is to minimize 
the number of patients recalled who do not have the screened condition, some patients, 
with further testing, will be shown to not have the disease and will therefore considered to 
be a false positive screen.  
ELSI: Too many false positives could potentially weaken public confidence in NBS 
programs and diminish the ability of health departments to provide accurate and helpful 
information.26  Other ELSI issues include concerns about the possible impact of false 
positive screening results on the stress of parents and the bonding between a parent and 
their newborn, as well as the increased cost and inconvenience of medical procedures 
needed to establish a diagnosis.27  Previous research suggests relatively limited 
psychosocial implications for most individuals and families, and studies have not shown 
increased health care utilization by parents with newborns who receive false positive 
screening results28 29.  However, the existing empirical research on false positives has been 
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somewhat limited with regard to the diversity of populations included, lack of subgroup 
analyses, and the need for more generalizable quantitative data.  Further research is 
needed to assess whether specific subgroups within the screened population may be at 
increased risk for higher levels of stress or other familial impacts of false positive results.  
Excessive numbers of false positive screening results may also put demands on state NBS 
program resources and the capacity of the health care system to respond.  Studies of the 
financial costs of false positives could provide estimates of system-wide impact.  
 
Key Question 3: What are the potential ELSI implications of false negative screening 
results related to a new condition? 
When implementing screening technology for a new condition, NBS programs must 
balance between testing approaches that maximize preventable death or disabilities that 
limit false negatives (cases that might be diagnosed at a later time) and unwarranted 
reassurance from a false negative result, as some confuse a negative screen as a negative 
diagnosis.  The potential impact of a false negative result will greatly depend on the 
condition screened and the implications of post symptomatic diagnosis.  Nevertheless, once 
the testing procedures (its analytical and clinical validity and utility) for a new condition 
reach the level of evidence necessary to justify using it in a state NBS program, the potential 
for false negative screening results should be very low since current approaches maximize 
test sensitivity.  
ELSI: The primary ELSI of false negative results relate to the potential false reassurance 
that these results cause for parents along with the potential physical harm from delayed 
diagnosis.  Subsequently, like false positives, increased numbers of false negative screens 
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may erode public trust and support for NBS programs.  Including ELSI issues in pilot 
studies should help to understand the impact of a false negative finding relative to public 
trust.  A key outcome of pilot studies aimed at assessing the potential for false negative 
screens could focus on creating policies and educational materials to help increase 
awareness about the potential for false negatives and mitigate the potential harms to 
newborns and families if conditions are detected and diagnosed late.  
 
Key Question 4: What are the potential ELSI implications of obtaining and reporting 
carrier status related to a new condition?  
Many of the conditions that may be piloted in NBS programs are inherited in a 
recessive manner, where both the mother and father are carriers of the condition.  Thus, 
screening for these conditions may identify newborns who are also carriers of a condition 
and who may not be clinically affected.  As a result, unique ELSI questions arise when a 
newborn’s carrier status is identified as part of the NBS process.  As a practical matter, NBS 
already detects carrier status for many of the screened conditions including sickle cell 
disease, cystic fibrosis and others15.   
ELSI: The core ELSI issues center on debates regarding disclosure and potential benefits 
and harms of carrier status information for newborns and families, and their implications 
for state policy decisions to disclose or not disclose carrier results as part of their screening 
program.30  Being a carrier for conditions screened may have health implications for 
individuals either in childhood or as an adult, including reproductive decision making.  
Additionally, there are arguments for assessing the social implications of screening for 
families as well as newborns.  For example, carrier results may be important for parents 
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considering their own future reproductive choices.30  NBS laboratories may report carrier 
findings as part of their perceived ethical obligation to disclose all testing results.  Similarly, 
parents may also lose trust in the NBS system if they perceive that the programs are 
withholding of information, such as carrier status from them.   
Alternatively, arguments could be made that there may be less of an ethical 
obligation to disclose carrier status, or even an obligation to not disclose, if the information 
would have no immediate impact on the health of a newborn.  This debate raises important 
questions about how we assess the social implications of screening and the impact of NBS 
information on newborns and families.  
Pilot studies could give researchers and states the opportunity to collect data on the 
impact of reporting carrier status to families, and then develop more informed policies 
regarding decisions to report carrier status results to health care providers and whether 
parents should have a choice about receiving carrier results.  For example, studies could 
investigate parental perceptions on how carrier information identified as part of NBS may 
be of significant value for the child across their lifespan.  Therefore, aside from 
programmatic decisions about reporting protocols, it is important to consider the ELSI 
issues for individuals and their families who might receive carrier information.31  
 
Key Question 5: What are the potential ELSI implications of indeterminate results 
related to a condition?  
In NBS there are sets of results for which the implications of the information 
obtained through screening may be unclear.  This may be especially true as more complex 
conditions are added to panels.  The addition of conditions to NBS panels with an unknown 
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age of onset, variable phenotypic features, unknown penetrance, or undetermined severity 
creates a situation in which parents or screened individuals, once subjected to diagnostic 
testing, might have uncertain knowledge concerning the presence or absence of disease.32 
ELSI:  When indeterminate results are returned to parents, there may be increased anxiety 
and stress related to when, or if, symptoms will occur in their children or themselves (for 
example, as with Krabbe Disease or Cystic Fibrosis Transmembrane Conductance 
Regulator-related Metabolic Syndrome33).  Delayed onset of a condition has the potential 
for labeling newborns as “diseased” before any actual manifestation of the disease, and 
without knowledge of potential morbidity.  Such newborns may become “patients-in-
waiting” as families and affected individuals embark on an uncertain future or lengthy 
diagnostic odyssey.9  Pilot studies of conditions with variable penetrance or variable 
phenotypic features can document the potential emotional and financial costs before such 
conditions are considered for inclusion in the RUSP.  For example, a pilot could assess the 
potential impact that receiving indeterminate or unclear results may have on families, 
including reassurance that they would be able to intervene at the earliest possible moment 
if symptoms arise, or exploring whether these results increase anxiety with regard to an 
unknown future and raise concerns about even minor symptoms.  
 
ELSI Questions Related to the NBS System   
The NBS System ELSI Issues focus on the impact of initiation and implementation of a 
new condition on a state NBS program or a State’s public health or health care delivery 
systems.  These questions begin with the decision to initiate screening for a particular 
condition and represent the implications that adding a condition (and its associated 
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screening and diagnostic tests) could have on the state health department (medical foods, 
child health insurance programs, etc.), the NBS program, screening laboratory, or health 
care delivery systems. 
 
Key Question 6: What are the cost or resource allocation implications for adding a new 
condition to the RUSP or a state panel?  
NBS programs require a great deal of resources to run an effective screening 
program for all infants born within their state.  Costs to state programs are not merely 
associated with the screening process itself, but also cover a number of crucial components 
of the entire NBS system including parent education, laboratory needs, and follow-up 
services.34  If the addition of a condition to the program’s NBS panel would be costly to the 
state NBS programs (equipment, training, personnel and other resources), and 
implementation might impact the program’s ability to function effectively in other areas, 
then assessing the net harms and benefits of screening for a particular condition is crucial 
to the decision-making process.  
ELSI: If adding a new condition to a NBS program disrupts its ability to maintain an 
effective NBS program, then expansion may prevent states from fulfilling their social and 
ethical obligation to assure that all newborns born within a state have the opportunity to 
be screened.  Therefore, program costs/resources related to new condition 
implementation should be an integral part of the piloting process.  These cost evaluations 
should include assessing the cost of educating parents, policy makers, health professionals 
and laboratory specialists; building or incorporating results reporting infrastructure, and 
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supporting public relations activities, including development of related materials 
(pamphlets, videos, etc.).  For some resource-poor programs, addition of new conditions 
for NBS may be more difficult than for resource-rich programs, and additional support may 
be necessary.  
 
Key Question 7: What are the health disparities or equity considerations related to 
adding a new condition to the RUSP or a state panel? 
Distributive justice questions in NBS include the availability and accessibility of 
short-term and long-term follow-up services and treatments.  While a NBS program may 
have a variety of resources available for newborns and their families, there may be 
challenges for medically underserved and/or geographically isolated families to access 
condition-related healthcare services at either the state or local levels.   
ELSI: Like resource allocation, equity considerations in NBS center on the ethical duty to 
assure that all newborns in a State have the opportunity to be screened and have 
appropriate follow up services.2  Barriers to services may include a lack of access to 
medical foods and formulas not covered by insurers35, expensive drugs, and difficulty 
obtaining expensive diagnostic procedures or medical interventions associated with a 
condition.  All have the potential to increase inequities for families and populations.  In 
some locations, sufficient subspecialty physician services may not exist and regional 
resources may be required.  Pilots should include an assessment of how NBS programs and 
the larger health care system could mitigate medical and related service inequities using 
approaches like telemedicine and regional service networks. 
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Key Question 8: What are the potential implications for public/parental trust in the 
NBS system or health department that might arise because of adding a new condition?  
Knowledge about NBS and its requirement is low among parents and families.36  
This awareness is exacerbated by the poor communication practices between NBS 
programs and prenatal health care practitioners.  Therefore, improving awareness and 
education about the NBS system is a key area of concern for state programs as patients 
become more active in their own healthcare and especially, as programs grow to include 
more conditions.  Trust in the NBS system is crucial to the success of screening and follow 
up services.  
ELSI: When developing pilots to study the implementation of a new condition, it is 
important to assess the potential impact that expanding a state NBS panel may have on 
public trust and other public perceptions. 37 38  Such assessments may require examining 
perceptions about program transparency and the decision-making process for adding new 
conditions, including how best to promote and manage input from parents, advocacy 
organizations, and other stakeholders.  Considerations should include the potential for 
public engagement and education concerning the addition of a new condition.  It is vital to 
assess whether unique characteristics of a new condition will merit special considerations 
when returning screening results to individuals who are members of populations already 
exhibiting mistrust of the government or the health care system.  For example, if a 
subgroup of the population has a higher risk of false positive screens, targeted educational 
and engagement activities may be required to that build greater trust in the NBS system as 
part of the larger health care community.  In addition, due to the complexity of NBS 
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technologies, treatments and disorders, communicating the purpose of, and results for, a 
pilot must include language and dialogue understandable to parents and families. 
 
Key Question 9: Does a condition raise any concerns regarding parental permission or 
challenges to the ethical or social justification for requiring population-based 
screening?  
Because NBS is a public health requirement, parents can opt-out of screening in 
most states (although not all) only for religious and/or philosophical reasons. 39   
Justification for the screening requirement is predicated on the principle that requiring 
active parental permission about NBS is not necessary because the  potential harm(s) from 
screening  are outweighed by the benefits from screening. . As genetic diseases are better 
understood as a result of population screening, some may argue that parents should be 
asked to “opt-in” for NBS that may include conditions for which clinical symptoms arise 
later in life and not during childhood.  That is, unless conditions need emergent diagnosis 
and treatment, there is less justification for a requirement to have NBS.  For example, an 
abnormal result for some lysosomal storage disorders (LSDs) might mean that the baby is 
an asymptomatic carrier, or that he (she) will experience late onset of the disease with 
milder symptoms, or that he (she) needs treatment immediately to prevent serious 
outcomes, depending on the LSDs.  Insurance companies may not pay for the additional 
testing required for a definitive diagnosis. 
ELSI: There are a number of different approaches programs can take with regard to 
parental permission, including a variety of opt-out and opt-in options.34  ELSI issues 
surrounding parental permission center on the need to weigh the public health necessity 
and benefits of screening with parental choice.  These ELSI questions are compounded 
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when interventions for diagnosed infants are not medical treatments.  As an example, early 
interventions may be initiated to minimize a cognitive delay in a condition such as Fragile X 
rather than working to eliminate the underlying defect in cognition.11  Obtaining parental 
permission for some NBS conditions while not requiring permission for others (thereby 
combining opt-in and opt-out processes) could create a tiered screening approach.40   Thus, 
the benefits of universal screening for conditions where the need for early detection and 
the availability of effective interventions are more certain would exist while allowing 
parents to choose screening for conditions that are in a pilot study or do not meet accepted 
criteria required for a universal mandate.  The potential harms for a two-tiered approach 
requires closer examination particularly with respect to the potential for creating an overly 
complicated system that might lead increased processing errors or decreased patient 
participation and social inequities.  Pilot studies could include questions and 
methodological designs that could test different types of parental permission and help 
programs assess the impact of different approaches.  
  
Applying Key ELSI Questions in Pilots   
These questions are intended to help research teams systematically consider the 
kinds of empirical ethics questions that can be assessed within pilot studies.  However, the 
utilization of these questions within the development of pilot studies will ultimately be 
shaped by the condition being studied.  It is our hope that research teams will develop a set 
of condition-specific ELSI questions to guide their own inquiry into the benefits and harms 
of population screening for their proposed condition.  The purpose of Table 1 is to provide 
teams of clinicians, advocates, and investigators with sample empirical questions that could 
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aid in identifying and assessing ELSI issues related to a specific condition.  
In addition to the use of this tool, we also encourage researchers designing pilot 
studies to include researchers engaged in ELSI related work in the planning and 
implementation of NBS pilots.  Doing so will allow for more robust identification of ELSI 
challenges related to a condition, or sets of conditions, and will aid in the integration of 
ELSI research methodologies into pilots, including surveys, interviews and other 
quantitative and qualitative research methods.  
Finally, it is also important to recognize the current challenges facing NBS pilots to 
integrate ELSI questions.  Generally, the disconnect stems from a lack of direction from 
funding agencies for NBS pilots to include specific ELSI concerns within the pilot study 
design.  Additionally, federal initiatives often lack sufficient funding or resources to include 
ELSI aims in pilot studies.  Rather, federal initiatives often target examination of the 
analytical and clinical validation of the screening test during the pilot without including 
specific ethical or legal questions.  Engaging NBS stakeholders to create new innovative 
approaches to NBS research will be vital in expanding the size, scope and quality of pilot 
studies, and could create new opportunities for integrating ELSI questions.  
 
Conclusion 
NBS pilot studies provide an invaluable opportunity to explicitly address the ELSI 
issues of screening by assessing the potential benefits and harms of screening and follow 
up, including diagnostic procedures, and medical interventions/treatments for newborns 
and their families.  We have delineated important questions for researchers to help in 
determining which ELSI should be included in pilot studies with the goal of identifying 
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research gaps, increasing the evidence base for assessing net benefits and harms of 
population based screening for newborn conditions, and promoting enhanced 
collaboration between researchers, state NBS programs, clinicians, advocacy organizations, 
ethicists, and social scientists to develop new approaches to assessing these difficult 
questions. 
It is also crucial to acknowledge that NBS is constantly evolving.  For example, some 
conditions being considered for NBS may have interventions that fall outside “traditional 
medical treatments”.  While screening for these conditions may provide net benefit to 
newborns and families, they may challenge the traditional metrics that have been used to 
determine when a condition is appropriate for addition to NBS panels.  Additionally, adding 
new testing technologies, such as genomic sequencing as an alternative or adjunct 
screening modality, also provides NBS programs with an opportunity improve the speed 
and quality of screening.  It will be essential that as screening programs evolve, the ELSI 
questions asked in pilot studies also reflect the changing landscape of NBS.   
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